Figure 1.
Proportion of human papillomavirus (HPV)-16 and -18 related cancers in Norway, by gender.
For oropharyngeal cancers, we considered three sub-sites: 1) oropharynx, 2) base of tongue and 3) tonsils. For all other cancers, we considered all histologies reported at each sub-site. Percentages have been rounded to the nearest whole number.
Table 1.
Selected inputs.
Table 2.
Projected reductions in HPV-related cancer incidence, by gender.
Figure 2.
Incremental cost effectiveness ratios (ICER) of vaccinating pre-adolescent girls and boys compared to vaccinating pre-adolescent girls only.
Shaded area represents the broad range of willingness-to-pay thresholds ($30,000–$100,000 per QALY gained) accepted across developed countries. Dotted line represents a threshold often cited in Norway ($83,000 per QALY gained).16 Cost per dose excludes the administration cost (≈$14 per dose).
Table 3.
Incremental cost-effectiveness ratios of including pre-adolescent boys in the childhood vaccination program compared to vaccination of pre-adolescent girls only.
Table 4.
Impact of parameter assumptions on the cost-effectiveness of including boys in a vaccination program against human papillomavirus (HPV) (including all HPV-16,-18,-6,-11 related conditions).
Figure 3.
Projected impact of vaccinating both pre-adolescent girls and boys at 71% coverage compared to increasing coverage to 90% for a girls-only program on non-cervical human papillomavirus (HPV)-16, -18 related cancers.
Dotted lines represent the theoretical maximum attributable fraction of HPV-16, -18 for each condition.